[HTML][HTML] Dendritic cells as shepherds of T cell immunity in cancer
In cancer patients, dendritic cells (DCs) in tumor-draining lymph nodes can present antigens
to naive T cells in ways that break immunological tolerance. The clonally expanded progeny …
to naive T cells in ways that break immunological tolerance. The clonally expanded progeny …
Facts and hopes in immunotherapy of pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancers to
treat. For patients with advanced and metastatic disease, chemotherapy has yielded only …
treat. For patients with advanced and metastatic disease, chemotherapy has yielded only …
ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer
Radiotherapy (RT) of colorectal cancer (CRC) can prime adaptive immunity against tumor-
associated antigen (TAA)–expressing CRC cells systemically. However, abscopal tumor …
associated antigen (TAA)–expressing CRC cells systemically. However, abscopal tumor …
Bispecific dendritic-T cell engager potentiates anti-tumor immunity
Immune checkpoint inhibition treatment using aPD-1 monoclonal antibodies is a promising
cancer immunotherapy approach. However, its effect on tumor immunity is narrow, as most …
cancer immunotherapy approach. However, its effect on tumor immunity is narrow, as most …
Strategies to overcome DC dysregulation in the tumor microenvironment
G Mestrallet, K Sone, N Bhardwaj - Frontiers in Immunology, 2022 - frontiersin.org
Dendritic cells (DCs) play a key role to modulate anti-cancer immunity in the tumor
microenvironment (TME). They link innate to adaptive immunity by processing and …
microenvironment (TME). They link innate to adaptive immunity by processing and …
Advancing translational research for colorectal immuno-oncology
Colorectal cancer (CRC) is a common and deadly disease. Unfortunately, immune
checkpoint inhibitors (ICIs) fail to elicit effective anti-tumour responses in the vast majority of …
checkpoint inhibitors (ICIs) fail to elicit effective anti-tumour responses in the vast majority of …
Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross‐priming
C Luri‐Rey, G Gomis, J Glez‐Vaz… - Immunological …, 2024 - Wiley Online Library
Antigen cross‐priming of CD8+ T cells is a critical process necessary for the effective
expansion and activation of CD8+ T cells endowed with the ability to recognize and destroy …
expansion and activation of CD8+ T cells endowed with the ability to recognize and destroy …
Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors
L López, LG Morosi, F La Terza, P Bourdely… - Nature …, 2024 - nature.com
Cross-presentation by type 1 DCs (cDC1) is critical to induce and sustain antitumoral CD8 T
cell responses to model antigens, in various tumor settings. However, the impact of cross …
cell responses to model antigens, in various tumor settings. However, the impact of cross …
Liver metastasis from colorectal cancer: pathogenetic development, immune landscape of the tumour microenvironment and therapeutic approaches
Y Wang, X Zhong, X He, Z Hu, H Huang, J Chen… - Journal of Experimental …, 2023 - Springer
Colorectal cancer liver metastasis (CRLM) is one of the leading causes of death among
patients with colorectal cancer (CRC). Although immunotherapy has demonstrated …
patients with colorectal cancer (CRC). Although immunotherapy has demonstrated …
Once upon a prime: DCs shape cancer immunity
M Zagorulya, S Spranger - Trends in cancer, 2023 - cell.com
Cytotoxic CD8+ T cells are potent killers of diseased cells, but their functional capacity is
often compromised in cancer. The quality of antitumor T cell immunity is determined during T …
often compromised in cancer. The quality of antitumor T cell immunity is determined during T …